{"entity":{"id":"da-trontinemab","kind":"drug","name":"Trontinemab","aka":[],"tldr":"Trontinemab is an investigational anti-amyloid antibody in Phase 3. It is not approved and is not for self-administration.","summary":"Roche’s Brainshuttle programme aims to improve brain uptake. Phase 3 safety and benefit are still being established. A trial listing is not a recommendation to join a study.","status":"phase-3","asOf":"2026-09-21","links":[{"label":"ClinicalTrials.gov NCT07170150","url":"https://clinicaltrials.gov/study/NCT07170150"}],"tags":["dementia-atlas"],"related":[],"cancers":["alzheimers-disease","mild-cognitive-impairment"],"sections":[],"technologies":[],"targets":["da-target-amyloid-beta"],"drugs":[],"companies":["da-roche"],"institutions":[],"pathways":[],"terms":[],"trials":["da-trial-trontier"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"modality":"mAb","mechanism":"Investigational amyloid-directed antibody designed for enhanced brain delivery (Brainshuttle).","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/da-trontinemab/","neighbours":{"cancer":[{"id":"alzheimers-disease","kind":"cancer","name":"Alzheimer’s disease","route":"/diagnoses/alzheimers-disease/"},{"id":"mild-cognitive-impairment","kind":"cancer","name":"Mild cognitive impairment","route":"/diagnoses/mild-cognitive-impairment/"}],"target":[{"id":"da-target-amyloid-beta","kind":"target","name":"Amyloid-beta","route":"/targets/da-target-amyloid-beta/"}],"company":[{"id":"da-roche","kind":"company","name":"Roche","route":"/companies/da-roche/"}],"trial":[{"id":"da-trial-trontier","kind":"trial","name":"TRONTIER 2 (trontinemab Phase 3)","route":"/trials/da-trial-trontier/"}]}}